Indian Emulsifiers Rights Issue 2026 — Ratio, Price & Record Date

Indian Emulsifiers Limited (NSE: IEML) has announced a rights issue of equity shares, confirmed by the Rights Issue Committee on 21 October 2026. The table below summarises the material terms disclosed by the company. This is the company's second rights issue in roughly twelve months.

Indian Emulsifiers Limited was incorporated on 5 December 2020 as a private company and converted to a public limited company on 5 January 2024. Its equity shares were listed on the NSE Emerge SME platform on 22 May 2024 following an initial public offer. The company is a manufacturer and supplier of specialty chemicals, working largely on an order-driven, customised-formulation basis.

Its product portfolio spans esters, esterquats, polyamides, polymerised surfactants, sulphates, amphoterics, phosphate esters, imidazolines, wax emulsions and formulated specialities — reported at more than 120 products across eight to nine end-use industries including personal care, cosmetics, cleaning, preservatives, metalworking, oil and gas, lubricants, mining and textiles. The registered office is in Worli, Mumbai, and the company has disclosed a manufacturing presence at MIDC Lote, Ratnagiri.

The promoter is Yash Tikekar, who serves as Managing Director. For FY26 the company reported revenue of about Rs 159.87 crore and profit after tax of about Rs 16.20 crore, with management describing capacity expansion as a key part of its growth plan.

A rights issue is a way for a listed company to raise fresh capital by offering new shares to its existing shareholders, usually at a price below the prevailing market price, in proportion to their current holding. It is a corporate action governed by SEBI's ICDR Regulations, 2018 and the Companies Act, 2013.

Because this is a 1:1 issue, a shareholder who does not apply or renounce sees their proportional ownership reduced relative to those who do subscribe, since the total share count can double on full subscription.

The company's board may extend the issue period, provided the issue does not remain open for more than 30 days from the opening date. No application may be withdrawn after the closing date.

The sequence below explains the practical significance of each milestone in the Indian Emulsifiers rights issue.

The detailed objects of this 2026 rights issue will be set out in the Letter of Offer, which the company has stated it will file with NSE Emerge and SEBI. As on the date of this report, a specific, line-item use of proceeds for the 2026 issue has not been publicly disclosed, and is therefore marked as pending the Letter of Offer rather than estimated.

For context only, the board approval of 16 May 2026 linked the broader capital-raising plan (a rights issue not exceeding Rs 51 crore) to the company's growth agenda, and separately the board approved a Rs 600 lakh investment for a 10.99% stake in Chemical Brothers Enterprises Private Limited. This context is derived from announcements and should be confirmed against the Letter of Offer before being treated as the formal objects of the issue. In its most recent prior rights issue (2025), the company had stated incremental working capital and construction of new factory premises as objects.

Promoter shareholding stood at about 32.64% as of September 2026, according to public shareholding data — down from about 48.11% a year earlier, a reduction associated with the earlier rights issue and subsequent changes in the capital base.

Whether the promoter intends to subscribe to the full entitlement in this 2026 issue has not been disclosed in the announcement reviewed, and is marked "Not Disclosed by the Company" pending the Letter of Offer. Readers should not assume full promoter subscription. The extent of promoter participation materially affects how ownership proportions shift after the issue, so it is an item to verify directly from the Letter of Offer when filed.

The table shows reported annual figures. Investors should note these are drawn from company results and public financial databases; where sources differ slightly on rounding, the company's own disclosures are preferred.

FY26 revenue grew about 57.93% year on year, with PAT up about 21.83%. Past performance does not guarantee future results. Figures appear to be reported on a standalone basis; consolidated statements should be used where available.

Observation (factual): Revenue has compounded rapidly, rising from about Rs 17.68 crore in FY22 to about Rs 159.87 crore in FY26, with profit after tax expanding alongside. However, ROCE has eased from a peak of about 31% in FY24 to about 15% in FY26, and working-capital intensity has increased — debtor days, inventory days and the cash conversion cycle have all lengthened over the period.

Interpretation (editorial): A fast-scaling specialty-chemicals manufacturer that is also building new capacity typically absorbs cash into working capital and capital expenditure. In that context, a rights issue can be read as a way to fund growth without adding materially to leverage. This is an analytical interpretation, not a company statement, and the actual objects remain to be confirmed from the Letter of Offer.

A full, line-item FY26 balance sheet was not uniformly available across the public sources reviewed, so specific asset, liability and net-worth figures for FY26 are marked as not fully verified here rather than estimated. What can be observed from available ratio data is a lengthening working-capital cycle (working-capital days rising toward the 200 mark by FY26) and a moderating return on capital.

If the rights issue is subscribed, the fresh equity would strengthen the net-worth base and could support working capital and capacity needs. The precise balance-sheet impact depends on the final subscription level and the confirmed use of proceeds, both of which should be read from the Letter of Offer and subsequent allotment disclosures.

Detailed operating, investing and financing cash-flow statements for FY26 were not consistently available in the public sources reviewed and are therefore not reproduced here, in line with a policy of not estimating undisclosed figures.

Conceptually, the rising working-capital intensity noted above suggests that a meaningful share of reported profit has been reinvested into receivables and inventory as the business scales. Accounting profit is not the same as cash generated, and a growing, order-driven manufacturer can be profitable while still needing external capital to fund the working-capital gap and capacity build — one reason capital-raising through a rights issue can arise even in a profitable year.

Promoter holding was about 32.64% as of September 2026 per public data. Because the issue is 1:1 and offered pro-rata to all eligible shareholders, if every shareholder subscribes in full, ownership proportions remain broadly unchanged even as the share count doubles.

Actual post-issue promoter, FII, DII and public shareholding splits will only be known from the post-allotment shareholding disclosure and are marked Not Disclosed until then.

Indian Emulsifiers operates in India's specialty chemicals sector, supplying emulsifiers, surfactants and formulated specialities into diverse end markets such as personal care, home care, textiles, metalworking, oil and gas and mining. Specialty chemicals is generally characterised by customised, application-specific formulations, closer customer relationships and value-added pricing relative to commodity chemicals.

Specific market-size and growth-rate figures for the relevant sub-segments are not reproduced here, to avoid presenting unverified industry statistics. As a small-cap, SME-listed manufacturer, the company competes with larger, better-capitalised specialty-chemicals players, which is a relevant backdrop when assessing its need for growth capital.

The company's reported competitive characteristics include a broad product portfolio (120-plus specialty chemicals), an order-driven and customised-formulation model, and exposure across multiple end-use industries, which can reduce dependence on any single sector. It has also disclosed securing direct export orders from a U.S. customer during 2026, indicating some international reach.

As a relatively young and small company, it faces the usual challenges of scale, bargaining power with larger customers and suppliers, and the capital intensity of expanding manufacturing capacity. Claims of market leadership are avoided here in the absence of comparable peer data for the specific segments in which it operates.

• Capacity expansion — management has described new capacity as a basis for targeted revenue growth (a forward-looking company expectation, not a guarantee).
• Revenue momentum — about 57.93% YoY revenue growth in FY26 extends a multi-year high-growth trajectory.
• Export orders — disclosed direct export orders from a leading U.S. customer point to a widening customer base.
• Broad product and end-market mix — diversification across eight-to-nine industries can cushion sector-specific demand swings.
• Fresh capital — rights-issue proceeds, subject to the confirmed objects, could fund working capital and capex to support the above.

Additional risks disclosed in the Letter of Offer should be read in full once available.

Subject to the confirmed objects, the capital raised could support opportunities such as funding incremental working capital for a rapidly scaling order book, financing capacity expansion, and strengthening the equity base to underpin future growth. The disclosed intent to acquire a stake in Chemical Brothers Enterprises (as part of the broader board-approved plan) could point to inorganic or supply-chain-related opportunities, though this should be confirmed against the Letter of Offer.

These are potential opportunities, not guaranteed outcomes, and they depend on effective deployment of proceeds and continued business execution.

Potential benefits are not guaranteed outcomes.

These describe possible outcomes, not certainties; confirmed facts are distinguished from risks throughout.

This is an educational discussion, not a recommendation to apply or to refrain. Factors an eligible shareholder may wish to weigh include:

• The Rs 27 price versus the current market price on the day they decide (not a stale reference).
• The company's fundamentals — strong revenue growth against easing ROCE and rising working-capital intensity.
• The confirmed use of proceeds, once the Letter of Offer is available.
• The implications of a second raise within twelve months.
• Their own tolerance for SME-segment volatility and the additional capital outlay required.
• Whether, if they do not wish to subscribe, selling the RE is preferable to letting it lapse.
• Their personal financial circumstances and objectives, ideally with a SEBI-registered adviser.

Pulling the threads together: the terms are clearly disclosed and confirmed (1:1 at Rs 27, Rs 49.50 crore, record date 27 October 2026). The company is growing revenue quickly but is also absorbing cash into working capital and capacity, which is a plausible reason to raise equity. The price offers an indicative discount to recent levels, but the stock has been highly volatile and has fallen sharply over the past year.

What the available evidence does not yet establish is the formal use of proceeds for this specific issue, the registrar and lead manager, and the promoter's subscription intent — all pending the Letter of Offer. These gaps are material to a full assessment and should be filled from primary documents before any decision.

On a neutral, fact-based view: the strategic rationale for a specialty-chemicals company in a steep growth phase to raise equity is understandable, given working-capital and capex needs. The pricing and 1:1 structure are shareholder-friendly in form, offering a discount and the choice to participate, renounce or exit the entitlement. The principal unanswered questions are the confirmed objects, the deployment track record of the 2025 proceeds, and the promoter's commitment this time. ShareBazaar Online has not issued, and does not issue, a formal investment recommendation; no analyst rating, price target or consensus figure is attributed in this article.

The Indian Emulsifiers rights issue is a 1:1 offer of 1,83,33,222 equity shares at Rs 27 each (Rs 10 face value plus Rs 17 premium), aggregating about Rs 49.50 crore. The record date was 27 October 2026, with subscription scheduled from 16 November to 1 December 2026 and Rights Entitlements trading as IEML-RE from 16 to 25 November. The price sits at an indicative discount to recent traded levels, and the company has delivered strong multi-year revenue growth, though ROCE has eased and working-capital intensity has risen. It is the company's second rights issue within roughly a year, and the formal use of proceeds, registrar, lead manager and promoter participation remain to be confirmed from the Letter of Offer. Eligible shareholders should read that document in full and consider their own circumstances before deciding. This review is educational and is not a recommendation to apply for, renounce, buy or sell any security.